BC
CABA icon

Boxer Capital’s Cabaletta Bio CABA Stock Holding History

Boxer Capital’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-540,000
Closed -$6.97M – 74
2023
Q2 		$6.97M Hold
540,000
– – 0.32% 52
2023
Q1 		$4.47M Hold
540,000
– – 0.22% 54
2022
Q4 		$5M Hold
540,000
– – 0.26% 50
2022
Q3 		$351K Hold
540,000
– – 0.02% 70
2022
Q2 		$572K Hold
540,000
– – 0.04% 73
2022
Q1 		$1.1M Hold
540,000
– – 0.06% 70
2021
Q4 		$2.05M Sell
540,000
-1,063,361
-66% -$11.3M 0.08% 66
2021
Q3 		$19.5M Hold
1,603,361
– – 0.68% 42
2021
Q2 		$13.8M Hold
1,603,361
– – 0.49% 60
2021
Q1 		$17.8M Hold
1,603,361
– – 0.6% 48
2020
Q4 		$20M Buy
1,603,361
+37,000
+2% +$480K 0.64% 44
2020
Q3 		$17M Hold
1,566,361
– – 0.59% 40
2020
Q2 		$17.4M Hold
1,566,361
– – 0.77% 35
2020
Q1 		$11.4M Hold
1,566,361
– – 0.78% 34
2019
Q4 		$21.9M Buy
+1,566,361
New +$18.6M 1.24% 23

Other funds holding CABA

FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital's CABA Position: Q3 2023 in Review

Boxer Capital sold out of Cabaletta Bio (CABA) in Q3 2023, closing a stake of 540,000 shares — an estimated $6.97M sold.

Boxer Capital first reported a position in CABA in Q4 2019 and held it in 15 quarters. The position peaked at $21.9M in Q4 2019. 97 funds tracked by Wall St. Rank hold CABA as of Q3 2023.

  • Boxer Capital reported no remaining Cabaletta Bio position as of Q3 2023 after selling out during the quarter.
  • Boxer Capital sold 540,000 Cabaletta Bio shares in Q3 2023, an estimated $6.97M.
  • Boxer Capital first reported a position in Cabaletta Bio in Q4 2019 and held it in 15 quarters.
  • Boxer Capital's Cabaletta Bio position peaked at $21.9M in Q4 2019.
  • 97 funds tracked by Wall St. Rank held Cabaletta Bio as of Q3 2023.

Based on Boxer Capital's 13F filing for Q3 2023, filed 14 Nov 2023.